BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/18/2024 7:36:02 AM | Browse: 178 | Download: 614
 |
Received |
|
2024-07-24 17:58 |
|
Peer-Review Started |
|
2024-07-24 17:58 |
|
First Decision by Editorial Office Director |
|
2024-09-25 06:46 |
|
Return for Revision |
|
2024-09-25 06:46 |
|
Revised |
|
2024-10-08 03:28 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-11-25 02:34 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-11-25 06:10 |
|
Articles in Press |
|
2024-11-25 06:10 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-11-27 00:37 |
|
Publish the Manuscript Online |
|
2024-12-18 07:36 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Prospects of elafibranor in treating alcohol-associated liver diseases
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Wei-Tong Cui, Hua-Ru Xue, Dian-Fang Wei, Xiao-Yu Feng and Kai Wang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Natural Science Foundation of Shandong Province, China |
ZR2019PC053 |
| Projects of Medical and Health Technology Development Program in Shandong Province, China |
202202020837, 202301040472 |
|
| Corresponding Author |
Wei-Tong Cui, MD, Professor, School of Basic Medicine, Qilu Medical University, No. 1678 West Renmin Road, Zibo 255300, Shandong Province, China. klnr727@qlmu.edu.cn |
| Key Words |
Elafibranor; Alcohol-associated liver diseases; Peroxisome proliferator-activated receptor; Lipid; Apoptosis; Steatosis; Inflammation; Fibrosis |
| Core Tip |
Elafibranor is an oral dual peroxisome proliferator-activated receptor α/δ agonist that has demonstrated efficacy in improving hepatic steatosis and inhibiting inflammation and fibrosis associated with nonalcoholic liver diseases. Alcohol-related liver disease (ALD), resulting from excessive alcohol consumption, also presents symptoms such as hepatic steatosis, inflammation, and fibrosis. However, the effectiveness of elafibranor in treating ALD remains unclear. A recent study by Koizumi et al revealed that elafibranor significantly reduced hepatic steatosis, apoptosis, and fibrosis in a mouse model of ALD. Despite the potential of elafibranor for ALD treatment appears promising, further experimental investigations and clinical trials are warranted. |
| Publish Date |
2024-12-18 07:36 |
| Citation |
Cui WT, Xue HR, Wei DF, Feng XY, Wang K. Prospects of elafibranor in treating alcohol-associated liver diseases. World J Gastroenterol 2025; 31(2): 99549 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i2/99549.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i2.99549 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
